Korean J Nephrol.  2006 May;25(3):365-373.

Long-term Prognosis of IgA Nephroapthy

Affiliations
  • 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. K780121@dsmc.or.kr

Abstract

BACKGROUND: IgA nephropathy (IgAN) is the most frequent primary glomerulonephritis in the world. Despite 20 years of research into this condition, much remains unknown about its pathogenesis and therapy. One major problem is that the prognostic evaluation and renal survival of IgAN is unreliable.
METHODS
A retrospective study was performed to clarify the prognostic factors and the long-term renal survival rates of this disease.
RESULTS
One hundred fifty-two patients with IgAN who followed-up at least 3 years after renal biopsy were included in this study. During a mean followed-up of 9.3 years after their renal biopsy (range:36-215 months), 33 of them (21.7%) had progressed to end-stage renal disease (ESRD). The actuarial renal survival rate was 97% at 5 years, and 85% at 10 years. Using univariate analysis, 5 risk factors for developing ESRD were identified:male sex, hypertension, heavy proteinuria, renal insufficiency at the time of biopsy, severe histopathologic findings such as subclass IV/V lesions by Haas' subclassification were associated with significant risk factors for developing ESRD. In multivariate regression analysis, only Haas' subclass IV/V lesions and renal insufficiency at the time of biopsy were the independent prognostic factors of IgAN.
CONCLUSION
In conclusion, further long-term prospective study with larger number of patients would be necessary to assess the prognostic factors in IgAN.

Keyword

IgA nephropathy; Long-term prognosis

MeSH Terms

Biopsy
Glomerulonephritis
Glomerulonephritis, IGA
Humans
Hypertension
Immunoglobulin A*
Kidney Failure, Chronic
Prognosis*
Proteinuria
Renal Insufficiency
Retrospective Studies
Risk Factors
Survival Rate
Immunoglobulin A
Full Text Links
  • KJN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr